Polypeptide With Localisation/Targeting Motif TRIZ Cases

Fusion polypeptides merge mutant MYC binding with transcriptional repression to overcome low efficacy and selectivity in cancer treatments.

A recombinant Nrf2 polypeptide activates endogenous antioxidant defenses to reduce inflammatory markers and mitigate oxidative stress in the eye.

Deleting endogenous lipase genes and introducing heterologous Candida lipase reduces fatty acid retinyl ester formation by 50-80%.

Segmenting chimeric antigen receptor components into separate transmembrane chains enables independent control over signal strength and flexibility.

Cyclic peptides induce autophagy by stabilizing key residues, resolving the trade-off between membrane penetration efficiency and cytotoxicity.

Segmenting receptor functions into activator and inhibitor modules resolves the trade-off between targeting accuracy and toxicity to healthy tissues.

Immunoreactive molecules target NY-BR-1 antigens without cross-reactivity to NY-BR-1.1, sparing healthy tissues.

Engineered Class C sortase variants form stable isopeptide bonds, overcoming proteolysis limits of conventional peptide linkages.

Targeted amino acid substitutions in the antibody hinge region prevent proteolytic cleavage during production, increasing functional immunoglobulin titers.

Engineered B cells utilize CD79a signaling domains to secrete therapeutic payloads, expanding treatment options beyond T cell therapies.

Segmented bi-functional domains anchor scFv recognition and intracellular signaling to kill cancer cells where conventional therapies fail.

Soluble hook fusion proteins with minimal ER retention signals enable reversible intracellular trafficking control, restoring lentivirus production efficiency.

An amphipathic shield domain fuses to integral membrane proteins, preventing aggregation and enabling detergent-free solubilization.

An engineered polypeptide with a condensate shifting domain forms liquid droplets to concentrate target molecules within cells.

Composite CAR constructs merge CD3zeta, CD28, and 4-1BB signaling pathways to overcome limited in vivo expansion of first generation therapies.

Optimized PR4 promoter and SP4 signal polypeptide sequences drive high-level extracellular secretion of IL-10 and amylase in lactic acid bacteria hosts.

Engineered gectosomes overcome membrane impermeability and lack of specificity by using fusogenic proteins for targeted intracellular delivery.

A DNA expression vector integrates a CMV promoter, His-Tag, and GFP marker to drive high-yield protein production.

C2-set Ig-like domain spacers in CARs reduce off-target activation and cytokine release while maintaining T cell persistence.

Genetically modified animals expressing human GITR enable precise preclinical evaluation of immune therapies.

Amino acid substitutions at positions 53 and 72 reduce toxicity while enhancing therapeutic efficacy for autoimmune disorders.

Segmented guide RNA molecules program Cas9 enzymes to target specific DNA sequences, overcoming affordability and setup barriers in scalable genome engineering.

Peptides activate MK2 to enhance endothelial barrier integrity, countering pulmonary edema without kinase inhibitor toxicity.

Knocking out suppressive genes like IKZF1 in CAR-T cells overcomes tumor-induced exhaustion, improving anti-tumor efficacy.

Segmented multi-antigen CAR T cells resolve specificity safety trade-offs by targeting tumor microenvironment markers.

Multi-antigen targeting CAR T cells reduce antigen escape and improve persistence by combining inducible co-stimulation with unified vector design.

Engineered signal peptides control cleavage site consistency during lambda antibody expression, resolving heterogeneity and improving yields.

Peptides binding chondroitin 6-sulfate transport cargo into cells, overcoming membrane impermeability.

Anti-TAT binding proteins enable precise detection of TAT fusion molecules while reducing complexity in antibody development.

Integrating a CD3 zeta-deficient CAR fragment into the endogenous CD3Z locus eliminates viral vector risks and graft-versus-host disease.

Segmenting the viral envelope into a cell-specific binding determinant and a fusogenic molecule maintains high viral titer while achieving precise targeting.

Multivalent HBV-Antiviruses display fusion proteins on viral-like particles to capture virions, overcoming resistance from drug-resistant strains.

Antibody fusion proteins transport biologically active peptides across biological barriers using genetically encoded cell-penetrating effector peptides.

Chimeric PC-FVII proteins activate Factor X via endothelial receptors to resolve the contradiction between hemostatic efficacy and thrombosis risk.

An IL2 peptide mimics the Panx1 intracellular loop to block channel activation and reduce ATP release.

Uracil stabilizing proteins inhibit glycosylase activity to preserve uracil for accurate C>T mutation introduction.

A dCas9-KRAB-MeCP2 fusion protein binds target nucleic acids to modulate gene expression via transcriptional repression.

CAAR cells express nicotinic acetylcholine receptor autoantigens to deplete pathogenic B cells, avoiding broad immunosuppression side effects.

Kinetoplastida host cells produce customized glycoproteins using engineered heterologous glycosyltransferases.

Nuclease-inactivated Cas9 fused with adenine deaminase directs guide RNA to plant genomes for precise A to G substitutions.

Engineered NKp30 variants overcome low B7H6 expression by binding with high affinity, enabling superior tumor cell killing and distinct cytokine profiles.

A binding triggered transcriptional switch activates encoded therapeutics in immune cells upon detecting glioblastoma priming antigens.

Plant-based expression of fused casein and beta-lactoglobulin eliminates animal agriculture, reducing greenhouse gas emissions and antibiotic resistance.

Tandem chimeric antigen receptors use human antibody variable regions to target CD19 and CD20 antigens on transduced T cells.

A transdermal peptide with nuclear localization ability penetrates the stratum corneum to deliver therapeutic macromolecules into cell nuclei.

An mRNA therapeutic composition encoding IGF1 promotes sustained muscle functional improvement and tissue regeneration in the urinary tract.

Importin-selective modifiers interrupt nuclear translocation of transcription factors, reducing inflammation without conventional drug side effects.

Segmented CAR molecules with optimized signaling domains resolve off-target cytotoxicity while maintaining targeting precision.

Genetically modified bacteria express enzymes with BMC-targeting signal peptides to aggregate enzymatic domains and concentrate substrates.